Full text loading...
-
Thiamine for Increasing Estimated Glomerular Filtration Rate in Type 2 Diabetes Mellitus with Chronic Kidney Disease Stage 3: A Randomized Controlled Trial
-
-
- 12 Dec 2024
- 20 Feb 2025
- 12 Jun 2025
Abstract
Introduction
Type 2 diabetes mellitus (T2DM) is the leading cause of chronic kidney disease (CKD). Thiamine has shown efficacy in microalbuminuria reduction, but its effect on estimated glomerular filtration rate (eGFR) is still uncertain.
Objectives
To determine the effect of thiamine on increasing eGFR in patients with T2DM with CKD stage 3.
Methods
This RCT was conducted in 35 T2DM with CKD stage 3 patients. 18 received 300 mg thiamine once daily (150 mg/capsule) and 17 received a placebo for 24 weeks. The primary outcome was the difference in the median change in the eGFR with thiamine at 24 weeks. Secondary outcomes included median changes within and between groups in the serum creatinine level, HbA1C level, urinary albumin level, total cholesterol level, LDL level, HDL level, triglyceride level, and adverse events.
Results
The baseline characteristics of the two groups were similar except for body mass index (BMI). After 24 weeks, the median change in eGFR was 1.59 ml/min/1.73 m2 of body-surface area (BSA) in thiamine group as compared to 1.78 ml/min/1.73 m2 of BSA in placebo group, leading to treatment difference of -0.19 ml/min/1.73 m2 of BSA (p = 0.61). The patients who received thiamine had a significant decrease in median HbA1c compared to the placebo (median change difference of -1.35, p < 0.01). The urinary albumin level and all lipid profiles were not significantly different between the two groups. No serious adverse events were reported.
Conclusion
The effects of the two agents on eGFR were not significantly different, but patients who received thiamine had a significant decrease in median HbA1C.
© 2025 Bentham Science Publishers